{"id":"idarubicin-ida","safety":{"commonSideEffects":[{"rate":"80-90","effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":"5-10","effect":"Cardiotoxicity (dose-dependent)"},{"rate":"30-50","effect":"Mucositis"},{"rate":"40-60","effect":"Nausea and vomiting"},{"rate":"20-30","effect":"Alopecia"},{"rate":"5-15","effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL1200976","moleculeType":"Small molecule","molecularWeight":"533.96"},"_dailymed":{"setId":"0a5a6d93-cc1e-4d7f-8da1-446c134503b3","title":"IDAMYCIN PFS (IDARUBICIN HYDROCHLORIDE) SOLUTION [PFIZER LABORATORIES DIV PFIZER INC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Idarubicin is an anthracycline chemotherapy agent that intercalates between DNA base pairs and inhibits topoisomerase II, an enzyme essential for DNA replication and transcription. This dual mechanism causes DNA strand breaks and prevents cancer cell proliferation, ultimately triggering apoptosis. It is particularly effective against hematologic malignancies due to its ability to penetrate leukemic cells.","oneSentence":"Idarubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents DNA unwinding, leading to cell death in rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:58.522Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML)"},{"name":"Acute lymphoblastic leukemia (ALL)"},{"name":"Chronic myeloid leukemia in blast crisis"}]},"trialDetails":[{"nctId":"NCT06744504","phase":"PHASE3","title":"Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-01-10","conditions":"AML, RUNX1-RUNX1T1 Fusion Protein Expression","enrollment":300},{"nctId":"NCT04190550","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-04","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","enrollment":24},{"nctId":"NCT04214249","phase":"PHASE2","title":"BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-17","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":49},{"nctId":"NCT05260528","phase":"PHASE2","title":"CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2023-05-03","conditions":"Acute Myeloid Leukemia","enrollment":248},{"nctId":"NCT07407140","phase":"PHASE3","title":"VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-30","conditions":"AML, Adult","enrollment":300},{"nctId":"NCT04107727","phase":"PHASE2","title":"Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2019-09-05","conditions":"Acute Myeloid Leukemia","enrollment":273},{"nctId":"NCT07486479","phase":"PHASE3","title":"Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-03-10","conditions":"Acute Myeloid Leukemia (AML)","enrollment":204},{"nctId":"NCT06928376","phase":"PHASE2","title":"A Multicenter RCT of \"3+7\" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-04-18","conditions":"Acute Myeloid Leukemia, First Line Therapy","enrollment":160},{"nctId":"NCT03591510","phase":"PHASE2","title":"A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2019-03-13","conditions":"FLT3-mutated Acute Myeloid Leukemia","enrollment":22},{"nctId":"NCT05453903","phase":"PHASE1","title":"A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-10-04","conditions":"Leukemia, Myeloid, Acute","enrollment":196},{"nctId":"NCT06713837","phase":"PHASE3","title":"IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2025-02-27","conditions":"Acute Myeloid Leukemia, Relapse/Recurrence","enrollment":339},{"nctId":"NCT03226418","phase":"PHASE2","title":"Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2017-07-07","conditions":"Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia","enrollment":75},{"nctId":"NCT04375631","phase":"PHASE1","title":"CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-12-03","conditions":"Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome","enrollment":120},{"nctId":"NCT03214562","phase":"PHASE1, PHASE2","title":"Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-09-26","conditions":"High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":116},{"nctId":"NCT07132684","phase":"PHASE3","title":"Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-08-31","conditions":"AML, Adult","enrollment":240},{"nctId":"NCT04263181","phase":"","title":"AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2020-01-29","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":80},{"nctId":"NCT06578247","phase":"PHASE3","title":"Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2024-11-19","conditions":"Leukemia","enrollment":700},{"nctId":"NCT06034470","phase":"PHASE1","title":"Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2023-12-18","conditions":"Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome","enrollment":30},{"nctId":"NCT02339740","phase":"PHASE3","title":"Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2015-07-21","conditions":"Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA","enrollment":158},{"nctId":"NCT06226571","phase":"PHASE1","title":"A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias","status":"RECRUITING","sponsor":"Syndax Pharmaceuticals","startDate":"2024-05-21","conditions":"Acute Myeloid Leukemias","enrollment":76},{"nctId":"NCT03165851","phase":"","title":"Efficacy Analysis of Comparison of CAMS（Chinese Academy of Medical Sciences）-2005 Trial and CAMS-2009 Trial for Pediatric Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2005-04-10","conditions":"Acute Myeloid Leukemia, Pediatric","enrollment":320},{"nctId":"NCT02028949","phase":"PHASE1","title":"Treatment of Cirrhosis-related Hepatocellular Carcinoma With the Intrahepatic Arterial Injection of an Emulsion of Lipiodol and Idarubicin (Zavedos®): Phase I Study","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2012-11-22","conditions":"Unresectable Non-metastatic Hepatocellular Carcinoma, Child A/B7 Cirrhosis","enrollment":15},{"nctId":"NCT07046078","phase":"PHASE2","title":"Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-26","conditions":"Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":20},{"nctId":"NCT03164057","phase":"PHASE2","title":"A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-06-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":206},{"nctId":"NCT03926624","phase":"PHASE3","title":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage","status":"TERMINATED","sponsor":"Delta-Fly Pharma, Inc.","startDate":"2019-11-22","conditions":"Leukemia, Myeloid, Acute","enrollment":167},{"nctId":"NCT07228273","phase":"PHASE2","title":"Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-12-12","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":102},{"nctId":"NCT06068621","phase":"PHASE2","title":"Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2023-03-01","conditions":"Acute Myeloid Leukemia","enrollment":200},{"nctId":"NCT03727633","phase":"PHASE2","title":"Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2018-07-19","conditions":"Carcinoma, Hepatocellular","enrollment":53},{"nctId":"NCT07297173","phase":"PHASE1","title":"Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia","status":"RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2025-12-01","conditions":"Relapsed Leukemia, Refractory Leukemia","enrollment":5},{"nctId":"NCT04077307","phase":"PHASE1","title":"A Study in Leukemia Patients With Karonudib","status":"RECRUITING","sponsor":"Thomas Helleday Foundation","startDate":"2019-12-03","conditions":"Leukemia","enrollment":9},{"nctId":"NCT04047641","phase":"PHASE1, PHASE2","title":"Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-10-22","conditions":"Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome","enrollment":80},{"nctId":"NCT02881086","phase":"PHASE3","title":"Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment","status":"COMPLETED","sponsor":"Goethe University","startDate":"2016-08","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":1023},{"nctId":"NCT05955261","phase":"PHASE2","title":"A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia","status":"SUSPENDED","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-07-25","conditions":"Acute Myeloid Leukemia","enrollment":70},{"nctId":"NCT03117751","phase":"PHASE2, PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma","enrollment":790},{"nctId":"NCT03330821","phase":"PHASE1, PHASE2","title":"Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2018-04-18","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Therapy-Related Acute Myeloid Leukemia","enrollment":53},{"nctId":"NCT02421939","phase":"PHASE3","title":"A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2015-10-20","conditions":"Leukemia, Acute Myeloid (AML)","enrollment":371},{"nctId":"NCT06001788","phase":"PHASE1","title":"Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Kura Oncology, Inc.","startDate":"2024-02-22","conditions":"AML, AML With Mutated NPM1, Hematologic Malignancy","enrollment":171},{"nctId":"NCT00534469","phase":"PHASE2","title":"Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2000-02-08","conditions":"Leukemia","enrollment":60},{"nctId":"NCT06311851","phase":"PHASE1, PHASE2","title":"Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases","status":"RECRUITING","sponsor":"Pardis Noor Medical Imaging and Cancer Center","startDate":"2025-06-01","conditions":"Cancer, Metastatic Cancer, Liver Metastases","enrollment":40},{"nctId":"NCT03589729","phase":"PHASE2","title":"Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-09-19","conditions":"Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow Nucleated Cells","enrollment":100},{"nctId":"NCT07232134","phase":"PHASE3","title":"The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia","status":"RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2025-07-24","conditions":"AML (Acute Myelogenous Leukemia), Down Syndrome (DS)","enrollment":100},{"nctId":"NCT06451861","phase":"PHASE2","title":"Randomized Study of ABC-14 Regimen Compared With \"3+7\" Standard Induction Therapy or AB-14 for ND AML","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2024-08-21","conditions":"Acute Myeloid Leukemia","enrollment":240},{"nctId":"NCT04801797","phase":"PHASE2","title":"Venetoclax + Azacitidine vs. Induction Chemotherapy in AML","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2021-05-20","conditions":"Acute Myeloid Leukemia","enrollment":172},{"nctId":"NCT06928662","phase":"PHASE1, PHASE2","title":"Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-23","conditions":"Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia","enrollment":36},{"nctId":"NCT02115295","phase":"PHASE2","title":"Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-05-19","conditions":"Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","enrollment":508},{"nctId":"NCT07059975","phase":"EARLY_PHASE1","title":"UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML","status":"RECRUITING","sponsor":"Joanna Yi","startDate":"2025-10-22","conditions":"Acute Myeloid Leukemia, Pediatric AML","enrollment":36},{"nctId":"NCT07223814","phase":"PHASE3","title":"Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)","status":"NOT_YET_RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2025-12","conditions":"Acute Myeloid Leukemia","enrollment":875},{"nctId":"NCT00801489","phase":"PHASE2","title":"Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-04-04","conditions":"Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1","enrollment":270},{"nctId":"NCT07180459","phase":"","title":"The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib：A Prospective, Single-arm, Multicenter, Observational Study","status":"NOT_YET_RECRUITING","sponsor":"Xuhua Duan","startDate":"2025-10-10","conditions":"Carcinoma, Hepatocellular Carcinoma","enrollment":118},{"nctId":"NCT03860844","phase":"PHASE2","title":"Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-08-06","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":67},{"nctId":"NCT02310321","phase":"PHASE1, PHASE2","title":"A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2015-02-26","conditions":"Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia","enrollment":97},{"nctId":"NCT07131059","phase":"NA","title":"MRD-positive AML Clinical Study","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-05-11","conditions":"AML, Adult","enrollment":120},{"nctId":"NCT07131501","phase":"PHASE2","title":"A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-08-11","conditions":"Hepatocellular Carcinoma, Immunotherapy, Preoperative","enrollment":48},{"nctId":"NCT06387069","phase":"PHASE3","title":"A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Hutchmed","startDate":"2024-04-26","conditions":"Acute Myeloid Leukemia","enrollment":316},{"nctId":"NCT07108530","phase":"PHASE2","title":"Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-06","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT06930105","phase":"PHASE2","title":"Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL","status":"NOT_YET_RECRUITING","sponsor":"Xianmin Song, MD","startDate":"2025-09-01","conditions":"Acute Lymphoid Leukemia (ALL)","enrollment":45},{"nctId":"NCT06265545","phase":"NA","title":"Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-02-22","conditions":"AML, Refractory, Relapsed","enrollment":120},{"nctId":"NCT07078591","phase":"PHASE2","title":"Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML","status":"RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2025-06-20","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT07059156","phase":"PHASE2, PHASE3","title":"Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-06-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":50},{"nctId":"NCT07053202","phase":"NA","title":"TACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"The First Hospital of Hebei Medical University","startDate":"2021-10-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":140},{"nctId":"NCT02185768","phase":"PHASE2","title":"Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2015-01","conditions":"Liver Cancer","enrollment":46},{"nctId":"NCT07028073","phase":"PHASE1, PHASE2","title":"A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-05-15","conditions":"Acute Myeloid Leukemia With T(8;21)(Q22;Q22), Acute Myeloid Leukemia With T(16;16)(P13;Q22), KIT Gene Mutation","enrollment":78},{"nctId":"NCT04687176","phase":"PHASE2","title":"Frontline Oral Arsenic Trioxide for APL","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2021-01-01","conditions":"Acute Promyelocytic Leukemia","enrollment":100},{"nctId":"NCT05827549","phase":"PHASE2","title":"Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Ho Joon Im","startDate":"2024-04-04","conditions":"Acute Lymphoid Leukemia","enrollment":90},{"nctId":"NCT02937662","phase":"PHASE2","title":"Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-10","conditions":"Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT06744556","phase":"PHASE2","title":"HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-01-21","conditions":"AML","enrollment":60},{"nctId":"NCT06066242","phase":"NA","title":"Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-10-01","conditions":"Acute Myeloid Leukemia","enrollment":90},{"nctId":"NCT06228781","phase":"NA","title":"Autologous Hematopoietic Stem Cell Transplantation for Refractory Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2026-12-01","conditions":"Multiple Sclerosis","enrollment":20},{"nctId":"NCT06741020","phase":"PHASE1, PHASE2","title":"Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-03-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":10},{"nctId":"NCT01822015","phase":"EARLY_PHASE1","title":"Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2013-03-15","conditions":"Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)","enrollment":55},{"nctId":"NCT02632708","phase":"PHASE1","title":"Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2015-12-31","conditions":"Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS)","enrollment":153},{"nctId":"NCT05586074","phase":"PHASE3","title":"HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML","status":"RECRUITING","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2023-03-03","conditions":"Leukemia, Acute Myeloid (AML)","enrollment":324},{"nctId":"NCT01518556","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Konkuk University Medical Center","startDate":"2011-07","conditions":"Leukemia, Myeloid, Acute","enrollment":49},{"nctId":"NCT06667973","phase":"PHASE2","title":"Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2025-06","conditions":"Acute Myeloid Leukemia, FLT3 Gene Mutation, Adult AML","enrollment":80},{"nctId":"NCT04953780","phase":"PHASE1","title":"2157GCCC:Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Dx AML","status":"ACTIVE_NOT_RECRUITING","sponsor":"West Virginia University","startDate":"2021-09-27","conditions":"Acute Myeloid Leukemia","enrollment":6},{"nctId":"NCT02834390","phase":"PHASE1","title":"Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2016-08-12","conditions":"Acute Myeloid Leukemia","enrollment":7},{"nctId":"NCT02688140","phase":"PHASE3","title":"Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"Technische Universität Dresden","startDate":"2016-06","conditions":"Acute Promyelocytic Leukemia","enrollment":135},{"nctId":"NCT06810791","phase":"PHASE3","title":"HVA vs IA/DA or VA in the Treatment of ND HR-AML","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-01-01","conditions":"Newly Diagnosed Acute Myeloid Leukemia With High Risk","enrollment":876},{"nctId":"NCT04778397","phase":"PHASE3","title":"Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2021-07-01","conditions":"Acute Myeloid Leukemia","enrollment":258},{"nctId":"NCT06529250","phase":"NA","title":"Intermediate-dose HAD Regimen for CEBPA Double-mutated AML","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-08-13","conditions":"AML","enrollment":148},{"nctId":"NCT06114082","phase":"PHASE2","title":"TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2023-04-28","conditions":"Hepatocellular Carcinoma, Liver Cancer","enrollment":128},{"nctId":"NCT06643962","phase":"NA","title":"Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy","status":"RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2024-10-31","conditions":"Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute","enrollment":83},{"nctId":"NCT02236013","phase":"PHASE1","title":"A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2015-01-07","conditions":"Acute Myeloid Leukemia","enrollment":80},{"nctId":"NCT03609060","phase":"PHASE2","title":"Dexamethasone Added to Intensive Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML)","status":"ACTIVE_NOT_RECRUITING","sponsor":"French Innovative Leukemia Organisation","startDate":"2018-08-24","conditions":"Acute Myeloid Leukemia","enrollment":120},{"nctId":"NCT06652685","phase":"PHASE2","title":"Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-10-30","conditions":"Acute Myeloid Leukemia (AML)","enrollment":218},{"nctId":"NCT05177731","phase":"PHASE3","title":"Venetoclax + Decitabine vs. \"7+3\" Induction Chemotherapy in Young AML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chen Suning","startDate":"2022-03-01","conditions":"AML, Adult, Chemotherapy Effect","enrollment":188},{"nctId":"NCT05557110","phase":"PHASE2","title":"Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL","status":"COMPLETED","sponsor":"Chen Suning","startDate":"2022-09-08","conditions":"B Acute Lymphoblastic Leukemia","enrollment":35},{"nctId":"NCT02920008","phase":"PHASE3","title":"Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2017-03-16","conditions":"Acute Myeloid Leukemia","enrollment":302},{"nctId":"NCT02096055","phase":"PHASE2","title":"Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-04-04","conditions":"Untreated Adult Acute Myeloid Leukemia","enrollment":44},{"nctId":"NCT02907359","phase":"PHASE3","title":"Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2017-01-13","conditions":"Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic","enrollment":417},{"nctId":"NCT06221683","phase":"PHASE2","title":"Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML","status":"RECRUITING","sponsor":"Children's Hospital of Soochow University","startDate":"2024-01-01","conditions":"AML, Childhood, Acute Myeloid Leukemia","enrollment":500},{"nctId":"NCT06316960","phase":"PHASE2","title":"Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation","status":"RECRUITING","sponsor":"Children's Hospital of Soochow University","startDate":"2024-03-01","conditions":"AML, Childhood, Relapse/Recurrence, Refractory AML","enrollment":50},{"nctId":"NCT02416388","phase":"PHASE2, PHASE3","title":"Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR","status":"RECRUITING","sponsor":"University Hospital, Angers","startDate":"2015-01","conditions":"Acute Myeloid Leukemia (AML)","enrollment":3100},{"nctId":"NCT02668653","phase":"PHASE3","title":"Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2016-09-01","conditions":"Acute Myeloid Leukemia, Leukemia","enrollment":539},{"nctId":"NCT02323022","phase":"PHASE3","title":"Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2014-12","conditions":"Acute Myeloid Leukemia","enrollment":618},{"nctId":"NCT03616470","phase":"PHASE3","title":"Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"GlycoMimetics Incorporated","startDate":"2018-10-15","conditions":"Acute Myeloid Leukemia","enrollment":388},{"nctId":"NCT06497062","phase":"PHASE2","title":"Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-09-04","conditions":"Acute Myeloid Leukemia","enrollment":47},{"nctId":"NCT06301425","phase":"NA","title":"MRD Response-adapted Allo-HSCT for Adverse-risk AML","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-05-24","conditions":"Acute Myeloid Leukemia","enrollment":178},{"nctId":"NCT06492408","phase":"PHASE2","title":"Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2024-07-01","conditions":"Hepatic Cancer, Surgery","enrollment":90},{"nctId":"NCT06492421","phase":"PHASE2","title":"Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2024-07-01","conditions":"Lung Cancer, Surgery, Non-small Cell Lung Cancer","enrollment":90}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"ACUTE PROMYELOCYTIC LEUKAEMIA"},{"count":2,"reaction":"CENTRAL NERVOUS SYSTEM LEUKAEMIA"},{"count":2,"reaction":"LEUKAEMIA RECURRENT"},{"count":1,"reaction":"ACUTE PROMYELOCYTIC LEUKAEMIA DIFFERENTIATION SYNDROME"},{"count":1,"reaction":"COGNITIVE DISORDER"},{"count":1,"reaction":"GAIT DISTURBANCE"},{"count":1,"reaction":"HYDROCEPHALUS"},{"count":1,"reaction":"STEM CELL TRANSPLANT"},{"count":1,"reaction":"VISUAL IMPAIRMENT"}],"_approvalHistory":[],"publicationCount":277,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["darubicin, IDA, Demethoxydaunor Ubicin"],"phase":"marketed","status":"active","brandName":"Idarubicin(IDA)","genericName":"Idarubicin(IDA)","companyName":"Chinese Academy of Medical Sciences","companyId":"chinese-academy-of-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Idarubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents DNA unwinding, leading to cell death in rapidly dividing cancer cells. Used for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Chronic myeloid leukemia in blast crisis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}